PortalPublikationenDisease Severity, Fever, Age, and Sex Correlate With SARS-Co...

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses

Standard

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. / Schlickeiser, Stephan; Schwarz, Tatjana; Steiner, Sophie; Wittke, Kirsten; Al Besher, Nabeel; Meyer, Oliver; Kalus, Ulrich; Pruß, Axel; Kurth, Florian; Zoller, Thomas; Witzenrath, Martin; Sander, Leif Erik; Müller, Marcel A; Scheibenbogen, Carmen; Volk, Hans-Dieter; Drosten, Christian; Corman, Victor M; Hanitsch, Leif G.

in: FRONT IMMUNOL, Jahrgang 11, 2021, S. 628971.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schlickeiser, S, Schwarz, T, Steiner, S, Wittke, K, Al Besher, N, Meyer, O, Kalus, U, Pruß, A, Kurth, F, Zoller, T, Witzenrath, M, Sander, LE, Müller, MA, Scheibenbogen, C, Volk, H-D, Drosten, C, Corman, VM & Hanitsch, LG 2021, 'Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses', FRONT IMMUNOL, Jg. 11, S. 628971. https://doi.org/10.3389/fimmu.2020.628971

APA

Schlickeiser, S., Schwarz, T., Steiner, S., Wittke, K., Al Besher, N., Meyer, O., Kalus, U., Pruß, A., Kurth, F., Zoller, T., Witzenrath, M., Sander, L. E., Müller, M. A., Scheibenbogen, C., Volk, H-D., Drosten, C., Corman, V. M., & Hanitsch, L. G. (2021). Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. FRONT IMMUNOL, 11, 628971. https://doi.org/10.3389/fimmu.2020.628971

Vancouver

Schlickeiser S, Schwarz T, Steiner S, Wittke K, Al Besher N, Meyer O et al. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. FRONT IMMUNOL. 2021;11:628971. https://doi.org/10.3389/fimmu.2020.628971

Bibtex

@article{8a847a4a74e9406795e24f6bd2162c19,
title = "Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses",
abstract = "Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses hint to a dose-response relationship between convalescent plasma neutralizing antibody levels and mortality. In particular, patients with primary and secondary antibody deficiency might benefit from this approach. However, testing of neutralizing antibodies is limited to specialized biosafety level 3 laboratories and is a time- and labor-intense procedure. In this single center study of 206 COVID-19 convalescent patients, clinical data, results of commercially available ELISA testing of SARS-CoV-2 spike-IgG and -IgA, and levels of neutralizing antibodies, determined by plaque reduction neutralization testing (PRNT), were analyzed. At a medium time point of 58 days after symptom onset, only 12.6% of potential plasma donors showed high levels of neutralizing antibodies (PRNT50 ≥ 1:320). Multivariable proportional odds logistic regression analysis revealed need for hospitalization due to COVID-19 (odds ratio 6.87; p-value 0.0004) and fever (odds ratio 3.00; p-value 0.0001) as leading factors affecting levels of SARS-CoV-2 neutralizing antibody titers in convalescent plasma donors. Using penalized estimation, a predictive proportional odds logistic regression model including the most important variables hospitalization, fever, age, sex, and anosmia or dysgeusia was developed. The predictive discrimination for PRNT50 ≥ 1:320 was reasonably good with AUC: 0.86 (with 95% CI: 0.79-0.92). Combining clinical and ELISA-based pre-screening, assessment of neutralizing antibodies could be spared in 75% of potential donors with a maximal loss of 10% of true positives (PRNT50 ≥ 1:320).",
keywords = "Adolescent, Adult, Age Factors, Aged, Antibodies, Neutralizing/immunology, Antibodies, Viral/immunology, Blood Donors, COVID-19/immunology, Convalescence, Female, Fever, Humans, Immunization, Passive, Male, Middle Aged, SARS-CoV-2/immunology, Severity of Illness Index, Sex Factors, Young Adult",
author = "Stephan Schlickeiser and Tatjana Schwarz and Sophie Steiner and Kirsten Wittke and {Al Besher}, Nabeel and Oliver Meyer and Ulrich Kalus and Axel Pru{\ss} and Florian Kurth and Thomas Zoller and Martin Witzenrath and Sander, {Leif Erik} and M{\"u}ller, {Marcel A} and Carmen Scheibenbogen and Hans-Dieter Volk and Christian Drosten and Corman, {Victor M} and Hanitsch, {Leif G}",
note = "Copyright {\textcopyright} 2021 Schlickeiser, Schwarz, Steiner, Wittke, Al Besher, Meyer, Kalus, Pru{\ss}, Kurth, Zoller, Witzenrath, Sander, M{\"u}ller, Scheibenbogen, Volk, Drosten, Corman and Hanitsch.",
year = "2021",
doi = "10.3389/fimmu.2020.628971",
language = "English",
volume = "11",
pages = "628971",
journal = "FRONT IMMUNOL",
issn = "1664-3224",
publisher = "Lausanne : Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses

AU - Schlickeiser, Stephan

AU - Schwarz, Tatjana

AU - Steiner, Sophie

AU - Wittke, Kirsten

AU - Al Besher, Nabeel

AU - Meyer, Oliver

AU - Kalus, Ulrich

AU - Pruß, Axel

AU - Kurth, Florian

AU - Zoller, Thomas

AU - Witzenrath, Martin

AU - Sander, Leif Erik

AU - Müller, Marcel A

AU - Scheibenbogen, Carmen

AU - Volk, Hans-Dieter

AU - Drosten, Christian

AU - Corman, Victor M

AU - Hanitsch, Leif G

N1 - Copyright © 2021 Schlickeiser, Schwarz, Steiner, Wittke, Al Besher, Meyer, Kalus, Pruß, Kurth, Zoller, Witzenrath, Sander, Müller, Scheibenbogen, Volk, Drosten, Corman and Hanitsch.

PY - 2021

Y1 - 2021

N2 - Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses hint to a dose-response relationship between convalescent plasma neutralizing antibody levels and mortality. In particular, patients with primary and secondary antibody deficiency might benefit from this approach. However, testing of neutralizing antibodies is limited to specialized biosafety level 3 laboratories and is a time- and labor-intense procedure. In this single center study of 206 COVID-19 convalescent patients, clinical data, results of commercially available ELISA testing of SARS-CoV-2 spike-IgG and -IgA, and levels of neutralizing antibodies, determined by plaque reduction neutralization testing (PRNT), were analyzed. At a medium time point of 58 days after symptom onset, only 12.6% of potential plasma donors showed high levels of neutralizing antibodies (PRNT50 ≥ 1:320). Multivariable proportional odds logistic regression analysis revealed need for hospitalization due to COVID-19 (odds ratio 6.87; p-value 0.0004) and fever (odds ratio 3.00; p-value 0.0001) as leading factors affecting levels of SARS-CoV-2 neutralizing antibody titers in convalescent plasma donors. Using penalized estimation, a predictive proportional odds logistic regression model including the most important variables hospitalization, fever, age, sex, and anosmia or dysgeusia was developed. The predictive discrimination for PRNT50 ≥ 1:320 was reasonably good with AUC: 0.86 (with 95% CI: 0.79-0.92). Combining clinical and ELISA-based pre-screening, assessment of neutralizing antibodies could be spared in 75% of potential donors with a maximal loss of 10% of true positives (PRNT50 ≥ 1:320).

AB - Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses hint to a dose-response relationship between convalescent plasma neutralizing antibody levels and mortality. In particular, patients with primary and secondary antibody deficiency might benefit from this approach. However, testing of neutralizing antibodies is limited to specialized biosafety level 3 laboratories and is a time- and labor-intense procedure. In this single center study of 206 COVID-19 convalescent patients, clinical data, results of commercially available ELISA testing of SARS-CoV-2 spike-IgG and -IgA, and levels of neutralizing antibodies, determined by plaque reduction neutralization testing (PRNT), were analyzed. At a medium time point of 58 days after symptom onset, only 12.6% of potential plasma donors showed high levels of neutralizing antibodies (PRNT50 ≥ 1:320). Multivariable proportional odds logistic regression analysis revealed need for hospitalization due to COVID-19 (odds ratio 6.87; p-value 0.0004) and fever (odds ratio 3.00; p-value 0.0001) as leading factors affecting levels of SARS-CoV-2 neutralizing antibody titers in convalescent plasma donors. Using penalized estimation, a predictive proportional odds logistic regression model including the most important variables hospitalization, fever, age, sex, and anosmia or dysgeusia was developed. The predictive discrimination for PRNT50 ≥ 1:320 was reasonably good with AUC: 0.86 (with 95% CI: 0.79-0.92). Combining clinical and ELISA-based pre-screening, assessment of neutralizing antibodies could be spared in 75% of potential donors with a maximal loss of 10% of true positives (PRNT50 ≥ 1:320).

KW - Adolescent

KW - Adult

KW - Age Factors

KW - Aged

KW - Antibodies, Neutralizing/immunology

KW - Antibodies, Viral/immunology

KW - Blood Donors

KW - COVID-19/immunology

KW - Convalescence

KW - Female

KW - Fever

KW - Humans

KW - Immunization, Passive

KW - Male

KW - Middle Aged

KW - SARS-CoV-2/immunology

KW - Severity of Illness Index

KW - Sex Factors

KW - Young Adult

U2 - 10.3389/fimmu.2020.628971

DO - 10.3389/fimmu.2020.628971

M3 - SCORING: Journal article

C2 - 33584731

VL - 11

SP - 628971

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

ER -